The Role of Pharmacotherapy and Managed Care Pharmacy Interventions in the Treatment of ADHD

Authors: Dr. Nirlepkumar Patel, Dr. Aakanksha Soni

DOI: https://doi.org/10.5281/zenodo.14851003

Short DOI: https://doi.org/g84qg4

Country: USA

Full-text Research PDF File:   View   |   Download

Abstract: “Attention-deficit/hyperactivity disorder (ADHD)”, which is one of most rampant neuro-developmental diseases, exerts a considerable influence on the relationships that people have with one another. In last 2 decades, there exists a significant increase in the quantity of clinical research and drugs those that have occurred licensed to address the symptoms of “attention-deficit hyperactivity disorder (ADHD)”. Clinical research was conducted between the years 2001 and 2019 to study a variety of “pharmacological & non-pharmacological methods to the treatment of attention deficit hyperactivity disorder (ADHD)”. Present research presents a quantitative summary of “the role of pharmacotherapy and managed care pharmacy intrusions in the treatment of ADHD” and variety of tactics through its analytical investigations. On clinicaltrial.gov, the researcher manually searched for the phrase “ADHD” and used the results of 695 interventional studies to compile the trial data that was used for this research. Alternatives to pharmaceutical treatments were investigated in almost eighty per cent of the research. These alternatives included a variety of behavioral intrusions, as of hypnotherapy, training at social skills, alterations to physical & sleep activity as well as deliberation. For the treatment of “attention-deficit hyperactivity disorder (ADHD)”, there an increasing interest at devices exists, adjuvant, and alternative techniques. There is around twenty percent of all research that is related to the pharmaceutical industry. Among the various types of medications, the most common types are “alpha-2 adrenergic receptor agonists, selective norepinephrine reuptake inhibitors, and stimulants of the central nervous system”. “Methylphenidate hydrochloride, lisdexamfetaminedimesylate, amphetamine sulfate, mixed amphetamine salts, and a combination of dexmethylphenidate hydrochloride and serdexmethylphenidate chloride” are some examples of the drugs that fall under this category. Pharmaceuticals such as “atomoxetine & viloxazine” are examples of such medications. The agonists’ “guanfacine hydrochloride & clonidine hydrochloride” are two examples of these compounds. Treatments for “attention-deficit hyperactivity disorder (ADHD)” without first obtaining the “Food and Drug Administration (FDA)” include a typical “antipsychotics (such as quetiapine & aripiprazole) and antidepressants (such as vortioxetine & bupropion hydrochloride)”. This research presents a review of “innovative pharmacological agents, non-pharmacological therapies, drug targets, and creative therapeutic choices”. Additionally, a discussion of quantitative trends in clinical trials is included in this research.

Keywords: Pharmacotherapy, Managed Care, Pharmacy Intrusions, ADHD, Treatment

Paper Id: 232120

Published On: 2020-01-15

Published In: Volume 8, Issue 1, January-February 2020

Share this